NCT06059144View on ClinicalTrials.gov

Induced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine

PHASE3RecruitingINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

November 28, 2024

Primary Completion Date

August 28, 2027

Study Completion Date

November 28, 2027

Conditions
Stroke, AcuteStroke, Ischemic
Interventions
DRUG

Peripheral intravenous norepinephrine

Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.

Trial Locations (1)

Unknown

RECRUITING

CHU de Bordeaux, Bordeaux

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER